Fremanezumab for Menstrual Migraine Prevention
Fremanezumab for the Prevention of Menstrually-related Migraine Attacks
Recruiting
Observational Study
Menstrual Migraine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 120 (estimated)
- Sponsor
- Insel Gruppe AG, University Hospital Bern · Other
Who this trial is looking for
This trial is looking for women who have menstrual migraine and are at least 18 years old. Participants will take fremanezumab and keep a headache diary for several months before and after starting the treatment.
Are You a Good Fit for This Trial?
You may be able to join if
- I am a woman aged 18 or older.
- I have a regular menstrual cycle of 21-32 days.
- I have been diagnosed with chronic or episodic migraine.
- I have had migraine with or without aura for at least one year.
- I experience at least 2 days of menstrual migraine during my last three periods.
- I have been keeping a daily headache diary for at least 3 months.
- I understand and will keep records in my headache diary for this trial.
- I am starting treatment with fremanezumab as advised by my doctor.
You may not be able to join if
- I have pure menstrual migraine.
- I am being treated with another anti-CGRP mAb.
- I am not receiving fremanezumab according to the treatment guidelines.
- I have used another anti-CGRP-based preventive medication in the last 6 months.
- I am taking part in another clinical trial for migraine.
- I have changed my hormone therapy during the study.
- I use progestin-only contraception.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks.
Participants diagnosed …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Premenopausal women of 18 years of age or older.
* Women with a regular cycle 21-32 days.
* The patient has a diagnosis of chronic or episodic migraine.
* Women suffering from migraine with or without aura according to International Headache Society (IHS) Classification (ICHD-…
Contacts